Cargando…

Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round

BACKGROUND: Colorectal cancer (CRC) is the most common cancer in Europe with a mortality rate of almost 50%. The prognosis of patients is largely determined by the clinical and pathological stage at the time of diagnosis. Population screening has been shown to reduce CRC-related mortality rate. Most...

Descripción completa

Detalles Bibliográficos
Autores principales: Stegeman, Inge, de Wijkerslooth, Thomas R, Mallant-Hent, Rosalie C, de Groot, Karin, Stroobants, An K, Fockens, Paul, Mundt, Marco, Bossuyt, Patrick MM, Dekker, Evelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407009/
https://www.ncbi.nlm.nih.gov/pubmed/22713100
http://dx.doi.org/10.1186/1471-230X-12-73
_version_ 1782239269957402624
author Stegeman, Inge
de Wijkerslooth, Thomas R
Mallant-Hent, Rosalie C
de Groot, Karin
Stroobants, An K
Fockens, Paul
Mundt, Marco
Bossuyt, Patrick MM
Dekker, Evelien
author_facet Stegeman, Inge
de Wijkerslooth, Thomas R
Mallant-Hent, Rosalie C
de Groot, Karin
Stroobants, An K
Fockens, Paul
Mundt, Marco
Bossuyt, Patrick MM
Dekker, Evelien
author_sort Stegeman, Inge
collection PubMed
description BACKGROUND: Colorectal cancer (CRC) is the most common cancer in Europe with a mortality rate of almost 50%. The prognosis of patients is largely determined by the clinical and pathological stage at the time of diagnosis. Population screening has been shown to reduce CRC-related mortality rate. Most screening programs worldwide rely on fecal immunochemical testing (FIT). The effectiveness of a FIT screening program is not only influenced by initial participation rate, but also by program adherence during consecutive screening rounds. We aim to evaluate the participation rate in and yield of a third CRC screening round using FIT. METHODS AND DESIGN: Four years after the first screening round and two years after the second round, a total number of approximately 11,000 average risk individuals (50 to 75 years of age) will be invited to participate in a third round of FIT-based CRC screening. We will select individuals in the same target area as in the previous screening rounds, using the electronic database of the regional municipal administration registrations. We will invite all FIT-negatives and all non-participants in previous screening rounds, as well as eligible first time invitees who have moved into the area or have become 50 years of age. FITs will be analyzed in the special technique laboratory of the Academic Medical Center of the University of Amsterdam. All FIT-positives will be invited for a consultation at the outpatient clinic. In the absence of contra-indications, a colonoscopy will follow at the Academic Medical Center or at the Flevohospital. The primary outcome measures are the participation rate, defined as the proportion of invitees that return a FIT in this third round of FIT-screening, and the diagnostic yield of the program. IMPLICATIONS: This study will provide precise data on the participation in later FIT screening rounds. This enables to estimate the effectiveness of CRC screening programs that rely on repeated FIT- screening, such as the one that will be implemented in the Netherlands in 2013.
format Online
Article
Text
id pubmed-3407009
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34070092012-07-28 Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round Stegeman, Inge de Wijkerslooth, Thomas R Mallant-Hent, Rosalie C de Groot, Karin Stroobants, An K Fockens, Paul Mundt, Marco Bossuyt, Patrick MM Dekker, Evelien BMC Gastroenterol Study Protocol BACKGROUND: Colorectal cancer (CRC) is the most common cancer in Europe with a mortality rate of almost 50%. The prognosis of patients is largely determined by the clinical and pathological stage at the time of diagnosis. Population screening has been shown to reduce CRC-related mortality rate. Most screening programs worldwide rely on fecal immunochemical testing (FIT). The effectiveness of a FIT screening program is not only influenced by initial participation rate, but also by program adherence during consecutive screening rounds. We aim to evaluate the participation rate in and yield of a third CRC screening round using FIT. METHODS AND DESIGN: Four years after the first screening round and two years after the second round, a total number of approximately 11,000 average risk individuals (50 to 75 years of age) will be invited to participate in a third round of FIT-based CRC screening. We will select individuals in the same target area as in the previous screening rounds, using the electronic database of the regional municipal administration registrations. We will invite all FIT-negatives and all non-participants in previous screening rounds, as well as eligible first time invitees who have moved into the area or have become 50 years of age. FITs will be analyzed in the special technique laboratory of the Academic Medical Center of the University of Amsterdam. All FIT-positives will be invited for a consultation at the outpatient clinic. In the absence of contra-indications, a colonoscopy will follow at the Academic Medical Center or at the Flevohospital. The primary outcome measures are the participation rate, defined as the proportion of invitees that return a FIT in this third round of FIT-screening, and the diagnostic yield of the program. IMPLICATIONS: This study will provide precise data on the participation in later FIT screening rounds. This enables to estimate the effectiveness of CRC screening programs that rely on repeated FIT- screening, such as the one that will be implemented in the Netherlands in 2013. BioMed Central 2012-06-19 /pmc/articles/PMC3407009/ /pubmed/22713100 http://dx.doi.org/10.1186/1471-230X-12-73 Text en Copyright ©2012 Stegeman et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Stegeman, Inge
de Wijkerslooth, Thomas R
Mallant-Hent, Rosalie C
de Groot, Karin
Stroobants, An K
Fockens, Paul
Mundt, Marco
Bossuyt, Patrick MM
Dekker, Evelien
Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
title Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
title_full Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
title_fullStr Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
title_full_unstemmed Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
title_short Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
title_sort implementation of population screening for colorectal cancer by repeated fecal immunochemical test (fit): third round
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407009/
https://www.ncbi.nlm.nih.gov/pubmed/22713100
http://dx.doi.org/10.1186/1471-230X-12-73
work_keys_str_mv AT stegemaninge implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT dewijkerslooththomasr implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT mallanthentrosaliec implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT degrootkarin implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT stroobantsank implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT fockenspaul implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT mundtmarco implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT bossuytpatrickmm implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround
AT dekkerevelien implementationofpopulationscreeningforcolorectalcancerbyrepeatedfecalimmunochemicaltestfitthirdround